ANTIMICROBIAL ACTIVITY OF SULBACTAM/CEFOPERAZONE COMPARISON WITH OTHER NEW CEPHEMS

DOI PubMed 1 Citations
  • DEGUCHI KOICHI
    Section of Studies, Tokyo Clinical Research Center
  • YOKOTA NOZOMI
    Section of Studies, Tokyo Clinical Research Center
  • KOGUCHI MASAMI
    Section of Studies, Tokyo Clinical Research Center
  • FUKAYAMA SHIGEMI
    Section of Studies, Tokyo Clinical Research Center
  • NISHIMURA YUKIKO
    Section of Studies, Tokyo Clinical Research Center
  • NAKANE YUTAKA
    Section of Studies, Tokyo Clinical Research Center
  • ODA SEIJI
    Clinical Laboratory 2nd Department, Tokyo Clinical Research Center (Department of Microbiology)
  • TANAKA SETSUKO
    Clinical Laboratory 2nd Department, Tokyo Clinical Research Center (Department of Microbiology)
  • KATO MIEKO
    Clinical Laboratory 2nd Department, Tokyo Clinical Research Center (Department of Microbiology)
  • SATO KUMIKO
    Clinical Laboratory 2nd Department, Tokyo Clinical Research Center (Department of Microbiology)
  • FUKUMOTO TORAO
    Fukumoto Clinic

Bibliographic Information

Other Title
  • 新鮮臨床分離株に対するSulbactam/Cefoperazoneの抗菌力

Search this article

Abstract

Antimicrobial activities of sulbactam/cefoperazone (SBT/CPZ) against 50 fresh clinical isolates of Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii, Enterobacter spp., Serratia marcescens, Proteus mirabilis, Proteus vulgaris and Pseudomonas aeruginosa were compared to those of CPZ, Cefotiam (CTM), Cefotaxime (CTX) and Latamoxef (LMOX). Minimal inhibitory concentrations (MIC's) of SBT and CPZ mixed in a ratio of 1: 1 were determined by the dilution method using MUELLER-HINTONa gar and expressed by absolute concentrations of CPZ.<BR>Antimicrobial activities of SBT/CPZ against principally penicillinase (PCase) producing bacteria, i.e., S. aureus, E. coli, K. pneumoniae, P. mirabilis, were superior to those of CPZ alone. The presence of SBT in concentrations around 0.39-1.56μ clearly enhanced CPZ's antimicrobial activities against these PCase producing strains.<BR>The synergistic antimicrobial effects of SBT in combination with CPZ were less pronounced against principally cephalosporinase (CEPase) producing bacteria, i.e., C. freundii, Enterobacter spp., S. marcescens, P. vulgaris, and P. aeruginosa, and exerted with SBT at concentrations around 3.13-12.5μ.<BR>Comparative antimicrobial activities indicated by MICso's of tested agents showed that SBT/CPZ had more stable activities against bacteria ranging from Gram-positive to Gram-negative bacteria than CTM, CTX and LMOX.<BR>MIC's of SBT/CPZ were higher than 25μ against 8% of S. aureus, 18% of C. freundii, 10% of Enterobacter spp., 26% of S. marcescens, 2% of P. vulgaris, and 18% of P. aeruginosa. These resistant strains against which the addition of SBT showed no synergism, may possess other mechanism of resistance than β-lactamase production.<BR>It is concluded that the presence of CPZ resistant strains is an actual current problem and not an imaginary future problem, and that the number of resistant strains against other new cephems which have different chemical structure from CPZ is increasing.<BR>When these present bacteriological environments are considered, the appearance of SBT/CPZ in the clinical practice is timely and meaningful.

Journal

Citations (1)*help

See more

Details 詳細情報について

Report a problem

Back to top